Ibrutinib Monotherapy in Early Stage Chronic Lymphocytic Leukemia (CLL) Without IWCLL/NCI-WG 2008 Treatment Indications But With High-Risk Features for Disease Progression
Phase of Trial: Phase II
Latest Information Update: 28 Sep 2018
Price : $35 *
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 24 May 2018 Status changed from not yet recruiting to recruiting.
- 02 May 2018 Planned initiation date changed from 1 Apr 2018 to 1 May 2018.
- 16 Feb 2018 Planned End Date changed from 1 Jan 2023 to 1 Jul 2021.